enow.com Web Search

Search results

1. Results from the WOW.Com Content Network

2. Fluticasone furoate/umeclidinium bromide/vilanterol - Wikipedia

   en.wikipedia.org/wiki/Fluticasone_furoate/...

   The combination fluticasone furoate/umeclidinium bromide/vilanterol product is approved by the US Food and Drug Administration with an indication for the maintenance treatment of a chronic lung problem called chronic obstructive pulmonary disease (COPD) in adults who (1) have already tried fluticasone furoate/vilanterol (brand name Breo Ellipta) but are still experiencing symptoms of airway ...

3. How To Be Active in Your Treatment Journey With COPD - AOL

   www.aol.com/active-treatment-journey-copd...

   Please see full Prescribing Information, including Patient Information, for TRELEGY. ... ©2023 GSK or licensor. FVUADVR230003 October 2023 Produced in USA. Sources.

4. GSK to cap out-of-pocket inhaler costs in US - AOL

   www.aol.com/news/gsk-cap-pocket-inhaler-costs...

   The cost cap would apply to all of its asthma and chronic obstructive pulmonary disease (COPD) medicines, including Advair Diskus, Advair HFA, and Trelegy Ellipta, and would apply to patients ...

5. List of GSK plc products - Wikipedia

   en.wikipedia.org/wiki/List_of_GSK_plc_products

   Trelegy Ellipta (fluticasone furoate, umeclidinium, and vilanterol inhalation powder) Treximet (sumatriptan and naproxen sodium) Trimovate (clobetasone butyrate) Ultiva (remifentanil hydrochloride) Valtrex (valaciclovir hydrochloride) Ventolin (salbutamol sulfate) Ventolin Expectorant (salbutamol sulfate/guaifenesin) Ventolin HFA (albuterol)

6. Glaxo/Innoviva File for Approval of Trelegy Ellipta in Japan

   www.aol.com/news/glaxo-innoviva-file-approval...

   Glaxo and Innoviva file for approval of Trelegy Ellipta in Japan for the treatment of COPD.

7. PAN Foundation - Wikipedia

   en.wikipedia.org/wiki/PAN_Foundation

   Through its more than 80 disease-specific financial assistance programs, PAN serves well over 100,000 patients each year from every US state and territory. [4] Without the PAN Foundation’s support, these patients would have faced impossible choices—with many simply going without their life-saving treatment.

8. GSK's Trelegy Ellipta meets key goal in late-stage ... - AOL

   www.aol.com/news/gsks-trelegy-ellipta-meets-key...

   British drugmaker GlaxoSmithKline Plc said on Thursday that its respiratory drug Trelegy Ellipta met the main goal of a late-stage asthma study, signalling a possible boost to its lung medicines ...

9. GSK2831781 - Wikipedia

   en.wikipedia.org/wiki/GSK2831781

   GSK2831781 is a monoclonal antibody being developed by GlaxoSmithKline (GSK) for autoimmune diseases. The antibody targets the T cell activation marker LAG-3, which is mainly expressed in inflamed tissues. In GSK's March 2015 Product development pipeline document the antibody is listed under 'Immuno-inflammation' candidates. [1]